UCB sues Sun over knockoff seizure drug; Indian pharmas struggle for beachhead in Japan;

gavel and books

@FiercePharma: Trending: Baxter fesses up to irregularities in China. Story | Follow @FiercePharma

@EricPFierce: ICYMI: Teva confronting tough time, sooner than later. Patent loss and soft quarter exemplify very real challenges. Article | Follow @EricPFierce

@CarlyHFierce: Roche signs agreement to make drug that prevents blindness in HIV patients available in developing nations. Release | Follow @CarlyHFierce

> Belgium's UCB sued Sun Pharmaceutical Industries over the latter's planned generic version of the seizure drug Vimpat. Report (reg. req.)

> Indian drugmakers are struggling to make a dent in Japan's generics market, the world's second largest, with only a few so far able to establish a presence there. Report

> The FDA expanded the age range for Novartis' ($NVS) meningococcal vaccine Menveo, allowing the drugmaker to offer one vaccine to infants, children and adolescents. Report

> Sanofi's ($SNY) Indian unit inked a deal with the country's largest wind-turbine maker for a 2.1 megawatt off-site windmill installation. Report

> The FDA gave its blessing to Bayer's animal health drugs ProstaMate and OvaCyst, used to manage reproduction. Report

> The FDA warned that acetaminophen can cause rare but serious skin diseases. Report

> Despite new price cuts in effect in India, some pharmacies are selling multinational drugmakers' products at the old prices. Report

> India's Piramal plans to raise about $61.57 million by issuing 11.75% commercial paper. Report

Medical Device News

@FierceMedDev: ICYMI Friday: Abiomed swings to loss on legal costs. Story | Follow @FierceMedDev

@MarkHFierce: ConforMIS, armed with $167.7M expanded series E, plots global marketing expansion. Report | Follow @MarkHFierce

@DamianFierce: Gore prevailed over St. Jude in a patent lawsuit over heart plugs. News | Follow @DamianFierce

@MichaelGFierce: Halozyme regrouping after ViroPharma trial flop. More from FierceDrugDelivery | Follow @MichaelGFierce

> M&A report: Theragenics agrees to $68M buyout. Story

> Stryker CEO: So far, so good after one year. Item

Biotech News

@FierceBiotech: Isis dumps rheumatoid arthritis effort after antisense drug flunks PhII. News | Release | Follow @FierceBiotech

@JohnCFierce: India revokes divisional patents on Herceptin. These emerging markets sure can be quite nettlesome. Report | Follow @JohnCFierce

@RyanMFierce: Computer-aided Compugen crashes cancer immunotherapy party with Bayer deal. More from FierceBiotechIT | Follow @RyanMFierce

> BioMotiv garners $46M for early-stage licensing deals, R&D work. Article

> The FDA OKs 5 blockbusters in slow start to 2013 drug approvals. Report

> Bayer aims at hot cancer immunotherapy race with $540M R&D deal. News

CRO News

> Charles River boosts sales as charges drag profits. Article

> INC expands in Japan as local market soars. Story

> Clinipace reaches into the north with CRO partnership. Item

> Quintiles posts flat revenue as charges swallow profits. Report

> Covance swings to profit despite tough early-phase market. More

> KKR buying RPS, planning to merge it with PRA. Article

Biotech IT News

> China pharma R&D drives expanded use of Medidata software. News

> Computer-aided Compugen crashes cancer immunotherapy party with Bayer deal. More

> Accelrys to ax 80 jobs after drop in quarterly profits. News

> Battle against breast cancer goes open source. Story

> Ex-Yahoo CEO backs genomics big data startup Bina. Article

And Finally... Antibiotic resistance in hospital-acquired illness is much greater than the Centers for Disease Control and Prevention (CDC) previously thought. Report